Glicksman, R. M., Metser, U., Valliant, J., Chung, P. W., Fleshner, N. E., Bristow, R. G., Green, D., Finelli, A., Hamilton, R., Stanescu, T., Hussey, D., Catton, C., Gospodarowicz, M., Warde, P., Bayley, A., Breen, S., Vines, D., Jaffray, D. A., & Berlin, A. (2020). [18F]DCFPyL PET-MRI/CT for unveiling a molecularly defined oligorecurrent prostate cancer state amenable for curative-intent ablative therapy: study protocol for a phase II trial. BMJ open, 10(4), . http://access.bl.uk/ark:/81055/vdc_100137792185.0x00000b